Lenvenib 4mg Capsule contains lenvatinib, a potent multi-kinase inhibitor used in the treatment of various malignancies. Lenvatinib exerts its antineoplastic effects by selectively inhibiting vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT signaling pathways, thereby impeding tumor angiogenesis and proliferation. Lenvenib is primarily indicated for the management of differentiated thyroid cancer (DTC) refractory to radioactive iodine therapy, advanced renal cell carcinoma (RCC) in combination with everolimus, and hepatocellular carcinoma (HCC) in patients who have not received prior systemic therapy. The recommended dosage varies based on the indication, patient weight, and tolerability, with careful dose adjustments required in cases of adverse reactions or hepatic impairment. Common adverse effects include hypertension, fatigue, diarrhea, decreased appetite, and proteinuria, necessitating regular monitoring of blood pressure, liver function, and renal parameters during therapy. Lenvenib should be administered under strict medical supervision, considering potential drug interactions and contraindications such as pregnancy and uncontrolled cardiovascular conditions. Patient adherence to prescribed dosing and follow-up evaluations are critical to optimizing therapeutic outcomes and minimizing risks associated with lenvatinib treatment.